Toggle search
Toggle menu
406
21
32
6.1K
Pharmacopedia
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Drilldown: Medicines

More actions

Choose a table:


Medicines > classes : Cathinone or Dissociative or GABAergic

Use the filters below to narrow your results.

generic:
brand:
None (38) · DXM (1) · DXO (1) · Quaalude (1) · Spravato (1) · THIP (1) · Xyrem (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · Active metabolite of DXM; NMDA antagonist (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Contains salvinorin A (1) · Fluorinated phenibut; GABAB agonist (1) · GABAA agonist (1) · GABAA potentiator (1) · GABAB agonist; alpha-2-delta calcium channel ligand (1) · GABAB agonist; GHB receptor agonist (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · Kavalactones; GABAA modulator; sigma receptor activity (1) · Methaqualone analogue; GABAA potentiator (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Prodrug of GHB (2) · Selective GABAA agonist (extrasynaptic delta subunit) (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3)
uses:
None (43) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (43) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (43) · 28 mg/device (each dose uses 2 devices) (1)
fda max:
None (43) · 84 mg per session (1)
routes:
None (43) · Intranasal (under direct medical supervision) (1)
onset:
None (43) · Within hours of first administration (1)
duration:
None (43) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)
halflife:
None (43) · ~7-12 hours (1)
bioavailability:
None (43) · ~48% intranasal (1)
pregnancy:
None (43) · Avoid; may cause fetal harm (1)
legal:
None (43) · Rx, Schedule III (US). REMS program required. (1)

Showing below up to 44 results in range #1 to #44.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"